| A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors (NCT05053139) | Novo Nordisk A/S | 2021-12-02 |
| Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10) (NCT05082116) | Novo Nordisk A/S | 2021-09-27 |
| Post-Marketing Surveillance (Use-results Surveillance) With Esperoct® (NCT04334057) | Novo Nordisk A/S | 2021-03-31 |
| Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol (NCT04682145) | Novo Nordisk A/S | 2020-12-09 |
| A Study Following Males With Haemophilia A on Prophylaxis With Esperoct® (NCT04574076) | Novo Nordisk A/S | 2020-10-23 |
| An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment (NCT04165135) | Hoffmann-La Roche | 2020-02-24 |
| A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6) (NCT03741881) | Novo Nordisk A/S | 2018-12-18 |
| Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B (NCT03276130) | Swedish Orphan Biovitrum | 2018-10-30 |
| A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia (NCT03660774) | Novo Nordisk A/S | 2018-09-27 |
| Register of Patients With haEmophilia A tReated With Afstyla® (NCT04675541) | CSL Behring | 2018-09-24 |
| Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients (NCT03179748) | Novo Nordisk A/S | 2018-06-20 |
| Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial (NCT03588741) | Novo Nordisk A/S | 2018-06-12 |
| A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A (NCT03528551) | Novo Nordisk A/S | 2018-04-30 |
| Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period (NCT03449342) | Novo Nordisk A/S | 2018-03-01 |
| Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients (NCT03695978) | Octapharma | 2018-02-13 |
| A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors (NCT03196297) | Novo Nordisk A/S | 2017-08-16 |
| A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B (NCT03055611) | Swedish Orphan Biovitrum | 2017-05-09 |
| Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A (NCT02994407) | Novo Nordisk A/S | 2017-01-30 |
| Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (NCT02938585) | Novo Nordisk A/S | 2016-12-12 |
| A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A (NCT02920398) | Novo Nordisk A/S | 2016-10-04 |
| TGA (Thrombin Generation Assay) and Prophylaxis in Haemophilia (NCT02781766) | Hospices Civils de Lyon | 2016-08-08 |
| Thrombin Generation Numerical Models Validation in Haemophilic Case (NCT02300519) | Centre Hospitalier Universitaire de Saint Etienne | 2015-03-01 |
| To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives (NCT02241694) | Novo Nordisk A/S | 2014-11-01 |
| To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan (NCT02207218) | Novo Nordisk A/S | 2014-08-04 |
| Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A (NCT02137850) | Novo Nordisk A/S | 2014-06-26 |
| Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A (NCT02035384) | Novo Nordisk A/S | 2014-06-05 |
| A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care (NCT02049099) | Swedish Orphan Biovitrum | 2014-03-01 |
| Project to Update the Study of Congenital Haemophilia in Spain (NCT01959555) | Novo Nordisk A/S | 2014-03-01 |
| Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects (NCT02084810) | Novo Nordisk A/S | 2014-03-01 |
| Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia (NCT01988532) | Novo Nordisk A/S | 2013-10-01 |
| A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors (NCT01949792) | Novo Nordisk A/S | 2013-09-01 |
| A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A (NCT01731600) | Novo Nordisk A/S | 2013-02-20 |
| Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A (NCT01692925) | Novo Nordisk A/S | 2012-12-01 |
| Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A (NCT01493778) | Novo Nordisk A/S | 2012-09-17 |
| Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. (NCT01489111) | Novo Nordisk A/S | 2012-08-03 |
| A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (NCT01631942) | Novo Nordisk A/S | 2012-06-26 |
| Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects (NCT01555749) | Novo Nordisk A/S | 2012-03-12 |
| Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A (NCT01480180) | Novo Nordisk A/S | 2012-01-30 |
| Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries (NCT01503567) | Novo Nordisk A/S | 2012-01-01 |
| Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients (NCT01436825) | Bayer | 2011-10-01 |
| BAY81-8973 Pediatric Safety and Efficacy Trial (NCT01311648) | Bayer | 2011-06-09 |
| Survey Evaluating the Psychosocial Effects of Living With Haemophilia (NCT01322620) | Novo Nordisk A/S | 2011-06-03 |
| A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A (NCT01365520) | Novo Nordisk A/S | 2011-06-01 |
| Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects (NCT01272206) | Novo Nordisk A/S | 2011-01-01 |
| Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients (NCT01288391) | Novo Nordisk A/S | 2011-01-01 |
| A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543 (NCT01238367) | Novo Nordisk A/S | 2010-11-01 |
| Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B (NCT01220141) | Novo Nordisk A/S | 2010-11-01 |
| Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (NCT01228669) | Novo Nordisk A/S | 2010-10-25 |
| Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors (NCT01234545) | Novo Nordisk A/S | 2010-10-01 |
| Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A (NCT01205724) | Novo Nordisk A/S | 2010-09-01 |
| Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A (NCT01138501) | Novo Nordisk A/S | 2010-06-01 |
| Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 (NCT00984126) | Novo Nordisk A/S | 2009-10-26 |
| A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers (NCT00951873) | Novo Nordisk A/S | 2009-07-01 |
| Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B (NCT00922792) | Novo Nordisk A/S | 2009-06-01 |
| Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects (NCT00840086) | Novo Nordisk A/S | 2009-04-01 |
| Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects (NCT00837356) | Novo Nordisk A/S | 2009-03-01 |
| Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy (NCT00638001) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2008-03-01 |
| Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database (NCT00853086) | Novo Nordisk A/S | 2008-01-01 |
| A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI (NCT02207894) | Haemophilia Centre Rhine Main | 2006-08-01 |
| Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State (NCT01562457) | Novo Nordisk A/S | 2005-11-01 |
| Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes. (NCT00245297) | Recoly N.V. | 2005-10-01 |
| A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A. (NCT02246894) | Bio Products Laboratory | 2003-11-01 |
| Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State (NCT01562587) | Novo Nordisk A/S | 2002-09-01 |
| An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery. (NCT02250482) | Bio Products Laboratory | 2001-11-01 |
| An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients. (NCT02246868) | Bio Products Laboratory | 2001-09-01 |